Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03228810 · ClinicalTrials.gov registry record
Genetic Biomarker Discovery for Metastatic Prostate Cancer
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 4
- Enrollment target
NCT03228810: Completed study, sponsored by Mayo Clinic.
NCT03228810 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03228810 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 4 participants
- Enrollment target
Study Summary
Biomarkers from circulating cell-free tumor DNA in peripheral blood will identify patients with metastatic prostate cancer diagnosed with C11 choline PET/CT who will benefit from metastasis-directed radiation, ablative therapies, and/or surgery. Tissue and blood will be collected before treatment. If patients receive androgen deprivation, then blood will be collected after neoadjuvant androgen deprivation but before radiation, ablative therapies, or surgery. Subsequent samples will be obtained at 3 months and 6 months following treatment, after which no further patient contact will occur.
Primary Outcome
tissue biopsy
Interventions
- OTHER Blood draw
- PROCEDURE Tissue biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-05-02 |
| Est. Completion | 2019-04-09 |
What the finished NCT03228810 record still lists
NCT03228810 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Blood draw is the first listed.
NCT03228810 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03228810 about?
NCT03228810 is a clinical study titled "Genetic Biomarker Discovery for Metastatic Prostate Cancer". Biomarkers from circulating cell-free tumor DNA in peripheral blood will identify patients with metastatic prostate cancer diagnosed with C11 choline PET/CT who will benefit from metastasis-directed radiation, ablative therapies, and/or surgery. Tissue and blood will be collected before treatment. I...
What is the current status of trial NCT03228810?
This trial is currently completed. The enrollment target is 4 participants. The study started on 2017-05-02. Estimated completion is 2019-04-09.
What interventions are being tested in trial NCT03228810?
The interventions under investigation include: Blood draw (OTHER), Tissue biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT03228810?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI